1. Home
  2. Knowledge Base
  3. References
  4. Intrathecal substance p-saporin in the dog: distribution, safety, and spinal neurokinin-1 receptor ablation.

Intrathecal substance p-saporin in the dog: distribution, safety, and spinal neurokinin-1 receptor ablation.

Wiese AJ, Rathbun M, Butt MT, Malkmus SA, Richter PJ, Osborn KG, Xu Q, Veesart SL, Steinauer JJ, Higgins D, Lappi DA, Russell B, Yaksh TL (2013) Intrathecal substance p-saporin in the dog: distribution, safety, and spinal neurokinin-1 receptor ablation. Anesthesiology 119(5):1163-1177. doi: 10.1097/ALN.0b013e3182a95164

Summary: Here the authors investigate the safety parameters of SP-SAP on purpose-bred beagles (currently in human clinical trials). The dogs received 1.5, 15, or 150 μg intrathecal injections of the conjugate. SP-SAP pharmacology and physiological effects were assessed by behavioral and functional observations, immunohistochemistry, ELISA, blood and urine analysis, histopathology, and in situ hybridization. The general conclusions include that neurokinin-1 receptor (NK1r) positive neuron loss is detectable as soon as 7 days after administration of SP-SAP, the neuron loss is permanent, toxicity is specific to NK1r-positive neurons, and, other than the 150 μg dose, NK1r neuron loss was restricted to the superficial dorsal horn.

Related Products: SP-SAP (Cat. #IT-07), SP-SAP (Cat. #IT-07)

Read the featured article in Targeting Trends.

Browse Articles

Need Support?

Can't find what you're looking for? Contact us, we're here to help!